Thank you for your interest in the broadly inclusive ALS clinical trial by Genervon. Due to the number of inquiries we received, we are unable to respond to emails on an individual basis. We are touched by many of the stories you have shared, and they motivate us to work even harder to bring our drugs to the market as soon as possible. Please visit our site http://www.genervon.com
for latest news.
This trial is registered at clinicaltrial.gov site # NCT 01854294 (http://clinicaltrial.gov/ct2/show/NCT01854294?term=01854294&rank=1
). Please read the protocol and see if you are qualify for this trial.
You should contact your doctors first and see if you are suitable for this trial. To participate in this trial, ALS patients should emailing your brief clinical history details including diagnosis, disease onset, disease status, prior therapy and response to prior therapy information to: Nichole Armstrong: email@example.com at Columbia NY and Michelle Parkinson: firstname.lastname@example.org at MGH Boston. Please copy your email to email@example.com.
Both trial sites are starting to enroll patients this month.
For those who are qualified and need to travel to treatment center, it is a short total 90 days trial requiring only 2 weeks of treatment (6 IV doses) and 2 evaluation visits at the center.
PS. THIS TRIAL IS FOR MODERATE ALS PATIENTS WITHIN 2 YEARS OF ALS ONSET.
Genervon Biopharmaceuticals LLC
1055 E. Colorado Blvd. Suite 500
Pasadena, CA 91106
This email is sent on behalf of Genervon Biopharmaceuticals, LLC. It may be privileged and contains confidential information intended only for the use of the recipient(s) named above. Use by anyone else is strictly prohibited. If you have received this communication in error, please notify us immediately.